GlassScriptPhysician profile
Asit K Jha
NPI 1497745632
$5,405.33
in general payments reported to CMS, 2019-2025
45 companies · $172 in 2025
The $172 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,019 · 2020: $355 · 2021: $1,055 · 2022: $1,936 · 2023: $670 · 2024: $199 · 2025: $172.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $582 · Education: $292 · Long Term Medical Supply Or Device Loan: $167.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $582.14 |
| Education | $291.98 |
| Long Term Medical Supply Or Device Loan | $166.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,519.16 | 2019-2023 | |
| Janssen Biotech, INC. | $373.75 | 2019-2025 | Talvey, Darzalex, Rybrevant |
| Amgen INC. | $353.58 | 2019-2023 | Lumakras, Blincyto, Kyprolis |
| Genentech USA, INC. | $295.49 | 2019-2023 | Gazyva, Lunsumio, Polivy |
| Pfizer INC. | $295.09 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $185.41 | 2019-2023 | Keytruda, Lynparza |
| E.R. Squibb & Sons, L.L.C. | $146.55 | 2019-2023 | Opdivo |
| Celgene Corporation | $146.42 | 2019-2023 | Reblozyl |
| Regeneron Healthcare Solutions, INC. | $130.23 | 2019-2022 | |
| Seagen INC. | $129.75 | 2019-2023 | Tukysa, Padcev |
| Clovis Oncology, INC. | $127.38 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $124.99 | 2019-2022 | |
| Gilead Sciences, INC. | $122.32 | 2021-2023 | Trodelvy |
| Astellas Pharma US INC | $116.41 | 2020-2022 | |
| Genzyme Corporation | $111.68 | 2019-2023 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Asit Jha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.